Stacie Hudgens, Chief Executive Officer, Strategic Lead Regulatory and Access, at COS, has an article published in Liver International: ‘Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C’
To view this article, please click here.
To find out more about Stacie Hudgens, please click here.